Dr. Bourgoin is a regular researcher at the Research Center of Quebec – Laval University and Professor in the Department of Microbiology-Infectiology and Immunology of the Faculty of Medicine at Laval University. His work focuses on lipid mediators of inflammation in systemic autoimmune diseases and dysfunction of innate immunity cells.
Dr. Bourgoin has published more than 100 articles in scientific journals (Google Scholar h-index of 39). His work has been the subject of several editorial reviews of scientific journals in 2108 (Molecular Pharmacology) and in 2011 (Journal of Leukocyte Biology). Dr. Bourgoin contributes to the influence of the CHU Research Centre and Laval University by organizing international symposia on neutrophils in immunity (2012, 2014, 2016, 2018).
Understanding early atherosclerosis in rheumatic autoimmune diseases:
Accelerated atherosclerosis, associated with systemic autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis, significantly increases the risk of cardiovascular events. The lipid mediators of inflammation play an amplifying role in the development of atherosclerosis, promoting the recruitment of immune system cells and the thickening of the vessel wall. Strategies to reduce cardiovascular risks associated with lupus erythematosus and rheumatoid arthritis remain to be clarified.
A new target to treat leukemia:
Myeloid leukemias are blood cancers whose origin is an anarchic production of white blood cells, from the bone marrow. These cells are usually immature, and unable to fight infections. Their presence also tends to disrupt the production of red blood cells, and cause a decline in the production of platelets. Genetic and epigenetic modifications alter the expression or function of proteins that act as positive or negative regulators of proliferation. These molecular switches abundant in leukemic myeloid cells act as positive regulators of proliferation, while inhibiting their differentiation into functional white blood cells.
2705, boulevard Laurier
T1-58
Québec, Québec
Canada G1V 4G2
Latest news
Assessment of Arf6 Deletion in PLB-985 Differentiated in Neutrophil-Like Cells and in Mouse Neutrophils: Impact on Adhesion and Migration
Journal ArticleMediators Inflamm, 2020 , 2020.
Abstract | Links: 
Phospholipase D2 in prostate cancer: protein expression changes with Gleason score
Journal ArticleBr J Cancer, 121 (12), 2019.
Abstract | Links:
Targeting the autotaxin - Lysophosphatidic acid receptor axis in cardiovascular diseases
Journal ArticleBiochem Pharmacol, 164 , 2019.
Abstract | Links:
Impairment of chemical hypoxia-induced sphingosine kinase-1 expression and activation in rheumatoid arthritis synovial fibroblasts: A signature of exhaustion?
Journal ArticleBiochem Pharmacol, 165 , 2019.
Abstract | Links:
Differential Effects of Inhibitor Combinations on Lysophosphatidic Acid-Mediated Chemokine Secretion in Unprimed and Tumor Necrosis Factor-α-Primed Synovial Fibroblasts
Journal ArticleFront Pharmacol, 8 , 2017.
Abstract | Links:
A Phosphorylatable Sphingosine Analog Induces Airway Smooth Muscle Cytostasis and Reverses Airway Hyperresponsiveness in Experimental Asthma
Journal ArticleFront Pharmacol, 8 , 2017.
Abstract | Links:
Regulators and Effectors of Arf GTPases in Neutrophils
Journal ArticleJ Immunol Res, 2015 , 2015.
Abstract | Links:
Role of mitogen- and stress-activated kinases in inflammatory arthritis
Journal Article4 (4), 2015.
| Links:
Chemical Hypoxia Brings to Light Altered Autocrine Sphingosine-1-Phosphate Signalling in Rheumatoid Arthritis Synovial Fibroblasts
Journal ArticleMediators Inflamm, 2015 , 2015.
Abstract | Links:
LPA Promotes T Cell Recruitment through Synthesis of CXCL13
Journal ArticleMediators Inflamm, 2015 , 2015.
Abstract | Links:
Active projects
- Role of phosphatidylserine-specific phospholipase A1 (PLA1A) in the pathogenesis of rheumatic diseases, from 2023-01-01 to 2025-12-31
Recently finished projects
- Role of autotaxin bound to platelet-derived microparticles to development of vascular damage in arthritis., from 2015-07-01 to 2023-03-31